Back to top

Cautious Hold on Fate Therapeutics: Promising Early Data for FT819 in Lupus, Awaiting Broader Evidence

Needham analyst Gil Blum has maintained their neutral stance on FATE stock, giving a Hold rating yesterday. Gil Blum has given his Hold rating due ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Fate Therapeutics, Inc. (FATE)